AU

The state of the hunt:

Pfizer/BioNTech asked the U.S. FDA to expand its authorization of their vaccine to adolescents.
  Numerous countries restricted the use of the AstraZeneca/Oxford shot to older people—or discontinued it altogether—even as regulators concluded the benefits outweighed the risks.
  COVAX affirmed that SII’s supply commitments to the initiative remain “legally binding” amid continued export restrictions from India.

 

Vaccines


The state of the hunt:

Pfizer and BioNTech plan to seek authorization of their vaccine for adolescents age 12-15 after promising Phase 3 results.
  J&J agreed to supply up to 400 million doses of Janssen’s jab to the African Union.
  Serum Institute of India launched clinical trials of its version of the Novavax vaccine candidate.

 

Vaccines


Approved or authorized vaccines
   
New data show lower efficacy for Pfizer/BioNTech: The…

The state of the hunt:

The European Union and India made new moves to curtail vaccine exports.
  COVAX warned of delivery delays.
  Pfizer and BioNTech launched a pediatric trial of their vaccine in children as young as 6 months.

 

Vaccines


Approved or authorized vaccines
   
New data, new questions for AstraZeneca: If AstraZeneca thought higher-than-expected efficacy results this week from the U.S.-based Phase 3 trial of AZD1222 would…

The state of the hunt:

Moderna began clinical trials of its vaccine in children.
  New vaccines from Iran and Vietnam entered human trials, and a Cuban shot reached Phase 3.
  France limited use of AstraZeneca’s vaccine to people 55 or older.

 

Vaccines


Approved or authorized vaccines
  
AZ jab is safe, EMA reaffirms—but will uptake suffer? A European Medicines Agency (EMA) risk assessment committee concluded a preliminary review…

The state of the hunt:

Two versions of the AstraZeneca/Oxford vaccine secured EUL from the World Health Organization.
  J&J has applied for both WHO and EMA authorization for Janssen’s Covid-19 vaccine.
  The Pfizer/BioNTech shot remains stable at higher temperatures than previously believed.

 

Vaccines


Approved or authorized vaccines
 
Pfizer and BioNTech are testing their vaccine in pregnant women through a 4,000-participant…

The state of the hunt:

Russia’s Sputnik V vaccine has reportedly been authorized in 26 countries.
  SAGE recommended that all countries proceed with planned rollouts of the AstraZeneca/Oxford jab, while the Africa CDC offered more cautious guidance, amid reports of low efficacy against viral variants.
  Tanzania has no plans to mount a Covid-19 immunization campaign.

 

Vaccines


Approved or authorized vaccines

SAGE backs AZ jab in all…

The state of the hunt:

COVAX has inked a deal for up to 40 million doses of Pfizer/BioNTech’s vaccine.
  India launched its mass vaccination campaign against Covid-19.
  China and India are both giving away vaccine doses to their neighbors.

 

Vaccines


Approved or authorized vaccines
 
China’s Sinovac jab more effective using three-week interval: A silver lining has emerged to last week’s middling news from the Butantan Institute’s…

The state of the hunt:

AstraZeneca commenced a U.S. Phase 3 trial of its AZD1222 vaccine candidate.
  Sanofi/GSK launched the first human trials of their investigational adjuvanted vaccine.
  Germany, Japan and Norway joined the COVAX Facility, which now has commitments from 78 upper- and upper-middle-income countries.

 

Vaccines

Phase 3 candidates:
 
AstraZeneca’s AZD1222 vaccine entered a United States-based Phase 3 trial targeting 30,000…

The state of the hunt:

Gilead says remdesivir showed 62% reduced mortality in severe patients
  Sinovac received approval to commence Phase 3 vaccine studies in Brazil
  Pfizer CEO hopes for October FDA vaccine approval
  Hep C drugs sofosbuvir and daclatasvir showed “provocative and encouraging” results against Covid-19

 

Vaccines

Clinical trials:

Brazil regulators approved a Phase 3 trial of Beijing-based Sinovac’s inactivated vaccine…